Clinical trials
Recurrent or Metastatic Solid Tumors clinical trials
Below are recruiting recurrent or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,361 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06471205RecruitingPhase 2
Study of BL-B01D1 plus immunotherapy for advanced triple-negative breast cancer
This study tests a new drug combination (BL-B01D1 plus an immunotherapy) for people with advanced triple-negative breast cancer who have not had prior treatment for their advanced disease. The goal is to see if the combination works better at shrinking or controlling the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07328243Recruiting
New treatment for thyroid cancer that spread to neck lymph nodes
This study tests a minimally invasive treatment called irreversible electroporation for thyroid cancer that has come back or spread to lymph nodes in the neck. It may be an option for people who can't have another surgery or for whom radioactive iodine therapy hasn't worked.
Guangzhou, GuangdongAges 18 years+ - NCT07648914RecruitingPhase 3
BL-B01D1 versus chemotherapy for advanced hormone-receptor-positive breast cancer
This trial tests a new targeted drug called BL-B01D1 against standard chemotherapy in patients with advanced breast cancer that is hormone-receptor-positive (HR+) and HER2-negative, and has stopped responding to hormone treatments. The goal is to see if the new drug works better or has fewer side effects.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05797168RecruitingPhase 1/Phase 2
Early study drug for advanced solid tumors, alone or with another drug
This Phase 1/2 study tests a new AstraZeneca cancer drug (AZD5335) to see how safely it can be given and how well it works in people with advanced solid tumors. You may get it alone or with another treatment, and you’ll need to provide tumor information (sometimes including a biopsy) for study planning.
Duarte, CaliforniaAges 18–130 - NCT06131840RecruitingPhase 1
Study of SGN-CEACAM5C for advanced solid tumors
This trial tests a new drug called SGN-CEACAM5C in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein on cancer cells to try to stop them from growing.
Phoenix, ArizonaAges 18 years+ - NCT05208762RecruitingPhase 1
PD-L1 antibody drug study for advanced lung and head/neck cancers
This Phase 1 trial tests a new experimental drug (PF-08046054/SGN-PDL1V) in people with advanced solid tumors that have not responded to standard treatment or can’t use it. It is designed to see how the drug works and how safe it is, with a focus on tumors that have PD-L1 seen on prior lab testing.
Birmingham, AlabamaAges 18 years+ - NCT06952660RecruitingPhase 4
Eye tests for people taking Tivdak for cervical cancer
This trial is for people with cervical cancer that has come back or spread and is getting worse after chemotherapy. It will check your eyes regularly while you take Tivdak to see how the drug affects them.
Phoenix, ArizonaAges 18 years+ - NCT02896335RecruitingPhase 2
Palbociclib and pembrolizumab for brain metastases
This study tests two drugs, palbociclib and pembrolizumab, for people whose solid tumors (like breast cancer or melanoma) have spread to the brain. The goal is to see if this combination can shrink or slow the growth of brain tumors that are progressing despite prior treatment.
Boston, MassachusettsAges 18 years+ - NCT07213609RecruitingPhase 1/Phase 2
Study of GSK5460025 for advanced solid tumors
This trial tests a new drug, GSK5460025, alone or with other cancer treatments, for people with advanced solid tumors that have spread or cannot be removed by surgery. It may help those whose cancer has a specific genetic feature (dMMR or MSI-H) or who have not responded to standard treatments.
Aurora, ColoradoAges 18 years+ - NCT06293898RecruitingPhase 1
Study of BL-M07D1 for HER2-positive solid tumors
This trial tests a new drug, BL-M07D1, for people with advanced solid tumors that have a protein called HER2. It is for patients who have already tried at least two other standard treatments.
Birmingham, AlabamaAges 18 years+ - NCT06788990RecruitingPhase 2/Phase 3
Study of ficerafusp alfa with pembrolizumab for advanced head and neck cancer
This study tests a new drug called ficerafusp alfa (BCA101) combined with the immunotherapy pembrolizumab for people with advanced head and neck cancer that has not been treated before. The goal is to see if adding ficerafusp alfa helps shrink tumors better than pembrolizumab alone.
Birmingham, AlabamaAges 18 years+ - NCT07554456RecruitingPhase 2/Phase 3
New Drug Combination for Advanced Esophageal Cancer
This trial tests a new drug called BL-B01D1 combined with an immune therapy (tislelizumab) and sometimes chemotherapy against standard chemotherapy for esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if this new combination works better and is safer than current treatment.
Beijing, Beijing MunicipalityAges 18–75 - NCT07287917RecruitingPhase 1/Phase 2
Testing a new drug combo for advanced breast cancer or melanoma
This trial tests a new combination of drugs (AMXT 1501, DFMO, and standard therapies) for people with advanced solid tumors, specifically breast cancer (ER+ HER2-) or melanoma that has progressed after other treatments. The goal is to see if this combination can help shrink tumors or slow their growth.
Tucson, ArizonaAges 18 years+ - NCT03016806Recruiting
Umbilical cord blood transplant from unrelated donors
This trial studies transplanting healthy blood-forming cells from an umbilical cord blood donor who is not related to you. It may help people with certain blood cancers, immune disorders, or other serious diseases when a standard transplant plan is needed.
Rochester, New YorkAges 2 months–75 years - NCT03122197RecruitingEarly Phase 1
Letrozole for recurrent high-grade brain tumors
This early-phase study tests letrozole, a hormone-blocking medicine, in adults with recurrent high-grade gliomas. The goal is to see if it can help control the tumor and is safe enough to study further.
Cincinnati, OhioAges 18 years+ - NCT03297606RecruitingPhase 2
Match your tumor test to a targeted cancer drug
This trial studies whether giving a targeted cancer medicine based on tumor genetic/protein test results can help people with advanced, incurable cancers live longer. You may be eligible if your cancer has a “potentially actionable” change on testing and you meet health and follow-up requirements.
Edmonton, AlbertaAges 18 years+ - NCT03495427RecruitingPhase 2/Phase 3
PSMA PET scan to find early prostate cancer spread
This study uses a PSMA PET scan to look for early spread of prostate cancer in men with higher-risk genetic test results (Decipher score above 0.45). It may help doctors spot metastases sooner so treatment decisions can be better targeted.
Tampa, FloridaAges 18 years+ - NCT03617133RecruitingPhase 2
MRI-guided radiation plus chemo for cervical cancer
This trial tests a more precise way to deliver radiation for locally advanced cervical cancer using MRI guidance during treatment, along with chemotherapy. It may help shrink tumors more effectively while aiming to reduce side effects by targeting the right areas.
ViennaAges 18–99 - NCT03646955Recruiting
Partial breast radiation versus no radiation after lumpectomy
This trial compares giving radiation only to part of the breast versus not giving radiation at all after breast-conserving surgery. It’s meant for women with early, hormone-driven breast cancer to see if skipping radiation can be safe and reduce treatment burden.
SantiagoAges 60 years+ - NCT03659448RecruitingPhase 3
Test drug that helps map colon and rectal cancer during surgery
This Phase 3 study tests SGM-101, a drug used during surgery to help doctors better outline primary, recurrent, and spread (metastatic) colorectal cancer. It may improve how completely tumors are identified and removed during an operation.
Duarte, CaliforniaAges 18 years+ - NCT03758976Recruiting
Study of scans in advanced breast cancer recurrence
This study looks at people with advanced breast cancer to better understand recurrence by using information from recent scans. It may help researchers improve how advanced disease is assessed and followed over time.
LundAges 18 years+ - NCT03767075RecruitingPhase 2
Basket trial matching cancer patients to targeted treatments
This trial tests whether matching your tumor’s DNA/RNA results to a specific cancer medicine can work better than standard options when cancer has spread or can’t be removed by surgery. You may be assigned to a “basket” (sub-study) based on the exact changes found in your tumor.
VillejuifAges 18 years+ - NCT03977233RecruitingPhase 2
Biopsies and FOLFIRINOX for non-metastatic pancreatic cancer
This Phase 2 study looks at different types (subtypes) of pancreatic tumors in people treated with FOLFIRINOX, a chemotherapy. It requires tumor biopsies before and after treatment to see how the tumor changes, which may help doctors better match treatments in the future.
Chapel Hill, North CarolinaAges 18–99 - NCT04151940Recruiting
PET/CT scan changes during chemo with immune therapy
This study looks at how PET/CT scan results change while you receive chemo plus an immune therapy (a PD-1/PD-L1 medicine) for stage IV lung cancer. The goal is to better understand what the scans mean during treatment, which may help guide care in the future.
Seattle, WashingtonAges 18 years+
Hear when a new Recurrent or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic solid tumors?
- Yes. Clin2 currently lists 3,361 recruiting recurrent or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.